Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
NCT07575399 on ClinicalTrials.gov · last registry update 2026-08-27
Recruiting now, toward 300 participants. Due to report 3 January 2028, alongside 22 other tracked readouts that quarter. Primary outcome, as filed: Percent Change from Baseline in Body Weight at Week 68. Sponsors move these dates routinely; any movement since this site started watching is listed below. maridebart cafraglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- RECRUITING
- Phase
- P3
- Sponsor
- Amgen
- Sponsor type
- Industry
- Enrollment
- 300
- Started
- 2026-05-11
- Primary completion
- 2028-01-03 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent Change from Baseline in Body Weight at Week 68
Conditions studied
Obesity or Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the maridebart cafraglutide page for this molecule’s full trial and approval history.